CA3102792A1 - Use of halogen compounds for the treatment and prevention of tissue injury and post-intensive care syndrome - Google Patents

Use of halogen compounds for the treatment and prevention of tissue injury and post-intensive care syndrome Download PDF

Info

Publication number
CA3102792A1
CA3102792A1 CA3102792A CA3102792A CA3102792A1 CA 3102792 A1 CA3102792 A1 CA 3102792A1 CA 3102792 A CA3102792 A CA 3102792A CA 3102792 A CA3102792 A CA 3102792A CA 3102792 A1 CA3102792 A1 CA 3102792A1
Authority
CA
Canada
Prior art keywords
iodide
subject
injury
disease
halogen compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3102792A
Other languages
English (en)
French (fr)
Inventor
Stephen A. Hill
Mark B. Roth
John W. LANGSTON
Michael L. MORRISON
Akiko Iwata
Michael Andrew INSKO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Faraday Pharmaceuticals Inc
Fred Hutchinson Cancer Center
Original Assignee
Faraday Pharmaceuticals Inc
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faraday Pharmaceuticals Inc, Fred Hutchinson Cancer Center filed Critical Faraday Pharmaceuticals Inc
Publication of CA3102792A1 publication Critical patent/CA3102792A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3102792A 2018-06-08 2019-06-07 Use of halogen compounds for the treatment and prevention of tissue injury and post-intensive care syndrome Pending CA3102792A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862682574P 2018-06-08 2018-06-08
US62/682,574 2018-06-08
US201862730927P 2018-09-13 2018-09-13
US201862730945P 2018-09-13 2018-09-13
US62/730,945 2018-09-13
US62/730,927 2018-09-13
PCT/US2019/036154 WO2019237065A1 (en) 2018-06-08 2019-06-07 Use of halogen compounds for the treatment and prevention of tissue injury and post-intensive care syndrome

Publications (1)

Publication Number Publication Date
CA3102792A1 true CA3102792A1 (en) 2019-12-12

Family

ID=68770655

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3102792A Pending CA3102792A1 (en) 2018-06-08 2019-06-07 Use of halogen compounds for the treatment and prevention of tissue injury and post-intensive care syndrome

Country Status (10)

Country Link
US (1) US20210252047A1 (https=)
EP (1) EP3801565A4 (https=)
JP (1) JP2021527130A (https=)
KR (1) KR20210018898A (https=)
CN (1) CN112469422A (https=)
AU (1) AU2019282820A1 (https=)
CA (1) CA3102792A1 (https=)
IL (1) IL279221A (https=)
MX (1) MX2020013306A (https=)
WO (1) WO2019237065A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX386702B (es) 2014-02-10 2025-03-19 Fred Hutchinson Cancer Center Tratamiento con halogeno de ataque cardiaco y lesion isquemica.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248335B1 (en) * 1997-10-29 2001-06-19 Symbollon Corporation Stabilized oral pharmaceutical composition containing iodide and iodate and method
CZ295765B6 (cs) * 1998-07-29 2005-10-12 Apa - Praha, S.R.O. Léčebný přípravek s virucidním účinkem
GB0525504D0 (en) * 2005-12-14 2006-01-25 Bristol Myers Squibb Co Antimicrobial composition
MX386702B (es) * 2014-02-10 2025-03-19 Fred Hutchinson Cancer Center Tratamiento con halogeno de ataque cardiaco y lesion isquemica.

Also Published As

Publication number Publication date
AU2019282820A1 (en) 2021-01-21
KR20210018898A (ko) 2021-02-18
EP3801565A4 (en) 2022-04-06
JP2021527130A (ja) 2021-10-11
EP3801565A1 (en) 2021-04-14
CN112469422A (zh) 2021-03-09
US20210252047A1 (en) 2021-08-19
MX2020013306A (es) 2021-05-12
WO2019237065A1 (en) 2019-12-12
IL279221A (en) 2021-01-31

Similar Documents

Publication Publication Date Title
US12016880B2 (en) Halogen treatment of heart attack and ischemic injury
ES2715049T3 (es) Formulación sólida de liberación rápida, preparación y uso de la misma
CN1150904C (zh) 分子碘的口服给药的药物组合物
EA017359B1 (ru) Способ и композиция для достижения бронхиальной релаксации
US20230285386A1 (en) IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
US20220395480A1 (en) Suspensions and diluents for metronidazole and baclofen
US20210252047A1 (en) Use of halogen compounds for the treatment and prevention of tissue injury and post-intensive care syndrome
WO2021257806A1 (en) Iodide for treatment of nonthyroidal illness syndrome
JP7761941B2 (ja) 脊髄損傷の治療剤
HK1231000B (en) Treatment of heart attack and ischemic injury with sodium iodide
HK1231000A1 (en) Treatment of heart attack and ischemic injury with sodium iodide
JPH059116A (ja) ３−オキシゲルミルプロピオン酸組成物並びに該組成物を主成分とする細胞変性抑制剤
Masaad et al. Improvement in the Characters of a Newly formulated Effervescent Ciprofloxacin Tablets by Enhancement in the Excipient Properties of the Formula
Hanna et al. Treatment of ascariasis in children with piperazine adipate
Neiffer et al. Cecal inversion and subsequent colocolic intussusception in a red wolf (Canis rufus gregoryi)
Rawlins et al. FORMULATION OF A READILY PREPARED D‐PENICILLAMINE ORAL LIQUID

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251124

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260129